PERU CAN ELIMINATE HEPATITIS
NATIONAL HEPATITIS ELIMINATION PROFILE

THE HEALTH BURDEN OF VIRAL HEPATITIS

**Hepatitis B virus (HBV)**

- **NO**
  - HBV elimination goal

- **YES**
  - Elimination of HBV mother to child transmission goal

**Hepatitis C virus (HCV)**

- **NO**
  - HCV elimination goal

**Action Plan**

---

**THE HEALTH BURDEN OF VIRAL HEPATITIS**

- **0.40%**
  - Number of persons living with HBV infection, 2015
  - Based on national survey

- **0.10%**
  - Number of persons living with HCV infection
  - Based on national survey

- **NO DATA**
  - Incidence

- **NO DATA**
  - Prevalence

REGIONAL AVERAGE IN THE AMERICAS:
- HBV: 0.3%
- HCV: 0.7%
**Progress Towards 2020 WHO Elimination Goals**

**Prevention of New Infections and Mortality**

- **HBV**
  - Percentage change in new infections, 2015-2019: NO DATA
  - Percentage change in deaths, 2015-2019: +0.36%

- **HCV**
  - Percentage change in new infections, 2015-2019: NO DATA
  - Percentage change in deaths, 2015-2019: +14%

Prevalence of HBsAg in children < 5 years (%), 2019: 0.04%

**Access to Recommended Vaccination, Testing and Treatment**

- Hepatitis B vaccination coverage for newborns, 2019: 88%
82% HepB 3 dose vaccine coverage for infants, 2019

WHO 2020 Target: 90%

Proportion of persons living with HBV diagnosed

NO DATA

WHO 2020 Target: 30%

HCV

Proportion of people diagnosed with HCV who have been cured

WHO 2020 Target: 30%

NO DATA

WHO 2020 Target -10%

Proportion of persons living with HCV diagnosed, 2019

NO DATA

WHO 2020 Target -10%

For persons who inject drugs (PWID), number of sterile needles per year

WHO 2020 Target: 200
POLICY ENVIRONMENT FOR THE ELIMINATION OF HEPATITIS

ACHIEVEMENTS

PREVENTION OF MOTHER TO CHILDREN TRANSMISSION

Policy for hepatitis B vaccination of newborns

Adopted

Recommendations for:

HBV testing of pregnant women

Adopted

HCV testing of pregnant women

Not Adopted

ROADBLOCK

There are no clear monitoring standards related to ministerial statements and technical guidance for hepatitis B and C.

Improvement of the epidemiological information system.

INNOVATIONS

ACHIEVEMENTS

The EMTCT Ministerial Declaration of HBV was signed in 2019 and updated HBV technical guidance on the prevention of mother-to-child transmission was published.

Universal screening for HBV screening in pregnant women.

Increased attention to the importance of hepatitis B vaccination, particularly for newborns with more than 80% coverage of hepatitis B vaccine administered at birth.

STRATEGIC INFORMATION

Routine official reports to monitor HBV and HCV

Not Adopted

Estimates of HBV and/or HCV economic burden

Not Adopted

Monitoring of HBV and HCV diagnosis and treatment

Not Adopted

PARTIAL ADOPTION: Only HBV for pregnant women

Mortality

Incidence

Prevalence

COALITION FOR GLOBAL HEPATITIS ELIMINATION

PERU • HEPATITIS ELIMINATION PROFILE
TESTING TO DIAGNOSE HBV AND HCV INFECTION

Testing recommendations for:

- **HBV**: Risk-based \(^\text{10}\)  
- **HCV**: Risk-based \(^\text{8}\)

No patient co-pays for HBsAg and anti-HCV testing

ROADBLOCK

*Testing policies are not routinely implemented. The number of people who are tested for HBV and HCV is small, and there is limited follow-up of patients who are tested.*

INNOVATIONS

*Use of multi-diagnostic molecular processing platforms.*

SIMPLIFICATION OF HCV TREATMENT GUIDELINES

- Local treatment guidelines \(^\text{8}\)  
- Simplified care algorithm: Less than 2 clinic visits during treatment \(^\text{8}\)
- Simplified care algorithm: Non-specialists can prescribe treatment \(^\text{8}\)
- Simplified care algorithm: No patient treatment co-pays
- No fibrosis restrictions \(^\text{8}\)
- No sobriety restrictions \(^\text{8}\)
- No genotyping \(^\text{8}\)
**Roadblock**

*Clinical guidelines for treatment are not implemented.*

**Innovation**

*Implementation of elastography for cirrhosis screening in endemic areas.*

**Achievements**

*In 2018, the “Technical Standard for the Prevention, Diagnosis and Treatment of Viral Hepatitis C in Peru” was adopted with a Ministerial Declaration.*

**Access and Registration of Medicines and Tests**

- **HCV:** Registration of originator medicines
  - Adopted

- **HCV:** Eligible for generic medicines
  - Adopted

- Licensed point-of-care PCR testing to detect HBV and HCV
  - Adopted

**Financing**

- Public budget line for HBV and HCV testing and treatment
  - Adopted

- GFTAM funds used to support the HBV or HCV program
  - Adopted

**Roadblock**

*Hepatitis has not always been considered a priority by the Government, compared to other diseases such as HIV.*

**Health Equity and Addressing Disparities**

- National strategy addresses populations most affected (that is, people who inject drugs, indigenous people, MSM, coinfected, etc.)
  - Adopted

- National anti-discrimination laws against persons living with hepatitis B and/or C
  - Adopted
**NEXT STEPS TOWARD ELIMINATION**

- The Ministry of Health should prioritize hepatitis and develop a national action plan with specific tests and treatment goals.
- A local coalition of stakeholders should be convened to advise the development of the action plan and policies to guide implementation, including representation from government, civil society, indigenous communities, and clinicians.
- Strategic information needs to be improved to allow a better understanding of barriers and progress towards goals at the national and regional levels.
- Improve links to care for people with positive HCV and HBV tests (for example, blood donors).
- Additional resources must be expanded to ensure indigenous people have access to hepatitis testing and treatment, including expanding training in indigenous languages.
- Decentralization of antiviral treatment towards the first level of care to increase the number of people treated.
- Technological transfer of serological marker testing to regional laboratories to improve the implementation of the testing guidelines.
- Continue implementing regional focused plans in endemic areas to promote the diagnosis, monitoring and treatment of chronic HBV carriers.
WORKING TOGETHER, WE WILL ACHIEVE ELIMINATION.

This National Hepatitis Elimination Profile (N-HEP) was developed by the Coalition for Global Hepatitis Elimination. Funding for this N-HEP was provided by Gilead Sciences. The Coalition for Global Hepatitis Elimination retained final control over the content.

The Coalition thanks Dr. Carlos Benites and Dr. Kelly Morales from the Ministry of Health, Dr. Martin Tagle and Edson Aguilar from Voces Ciudadanas for their review and comments.